June 19, 2019
MERCK
A Six Month Phase II/III, Randomized, Double- Blind, PlaceboControlled Clinical Trial to Evaluate the…
Read More
June 19, 2019
TAKEDA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus…
Read More
June 19, 2019
ABBOTT (M10889)
A Global Multicenter, Randomized,Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of…
Read More
June 19, 2019
ABBOTT (M12-073)
A Double-Blind, Randomized, Parellel-Arm,Multicenter Study to Determine the Dose Response of Methotrexate (MTX) in CombinationTherapy…
Read More
June 19, 2019
NOVARTIS (CACZ885M2301)
A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent…
Read More
June 19, 2019
NOVARTIS (CQVA149A2340)
A multi-center, randomized, double-blind, 52-week study to assess the safety of QVA149 compared to QAB149…
Read More
June 19, 2019
NOVARTIS (CAIN457F2302)
Novartis Pharmaceuticals trial entitled: A randomized, double-blind, placebo- controlled study of secukinumab to demonstrate the…
Read More
June 19, 2019
NOVARTIS (CAIN457F2206)
A randomized, double-blind, placebo-controlled regimen finding study of efficacy, safety and tolerability of secukinumab at…
Read More
June 19, 2019
ELI LILLY I4V-MC-JADW
“A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104)…
Read More
June 19, 2019
ELI LILLY H9B-MC-BCDS
“A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of…
Read More
